What is the difference between Dulaglutide and Semaglutide?

Dulaglutide is classified as: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment). Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.

Is Dulaglutide or Semaglutide approved?

Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Dulaglutide and Semaglutide?

Peptide Science Daily tracks 138 registered clinical trials for Dulaglutide (evidence grade A) and 500 for Semaglutide (evidence grade A).

Compound comparison

Dulaglutide vs Semaglutide

This page sets Dulaglutide and Semaglutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Dulaglutide
Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment)
Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism: Dulaglutide
In plain terms, dulaglutide copies a natural gut hormone that lowers blood sugar and curbs appetite.
Semaglutide
In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA): Dulaglutide
Approved. Trulicity for type 2 diabetes (2014); an indication to reduce major adverse cardiovascular events in adults with type 2 diabetes was added in 2020.
Semaglutide
Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA): Dulaglutide
Authorized (Trulicity) for type 2 diabetes (marketing authorization granted 2014).
Semaglutide
Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA): Dulaglutide
Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.
Semaglutide
Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA: Dulaglutide
Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.
Semaglutide
Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade: Dulaglutide
A
Semaglutide
A
Tracked clinical trials: Dulaglutide
138
Semaglutide
500
Full profile: Dulaglutide
Dulaglutide profile
Semaglutide
Semaglutide profile

Comparison of Dulaglutide and Semaglutide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Dulaglutide	Semaglutide
Class	Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment)	Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism	In plain terms, dulaglutide copies a natural gut hormone that lowers blood sugar and curbs appetite.	In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA)	Approved. Trulicity for type 2 diabetes (2014); an indication to reduce major adverse cardiovascular events in adults with type 2 diabetes was added in 2020.	Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA)	Authorized (Trulicity) for type 2 diabetes (marketing authorization granted 2014).	Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA)	Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.	Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA	Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.	Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade	A	A
Tracked clinical trials	138	500
Full profile	Dulaglutide profile	Semaglutide profile

Common questions

What is the difference between Dulaglutide and Semaglutide?: Dulaglutide is classified as: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment). Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.
Is Dulaglutide or Semaglutide approved?: Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Dulaglutide and Semaglutide?: Peptide Science Daily tracks 138 registered clinical trials for Dulaglutide (evidence grade A) and 500 for Semaglutide (evidence grade A).